Navigation Links
ADVENTRX Pharmaceuticals Provides Update on ANX-514
Date:2/15/2011

better represent the pharmacokinetics of docetaxel and are better predictors of clinical effects and outcomes.    

The FDA did not agree that evaluating bioequivalence using unbound docetaxel concentrations was warranted and determined that data from Study 514-01 was not adequate to conclude that the short period of higher exposure to total docetaxel concentrations observed early in the treatment cycle with ANX-514 do not adversely affect the safety or efficacy of ANX-514 relative to Taxotere.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates principally for the treatment of cancer.  More information can be found on the Company's web site at www.adventrx.com.  

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the potential for submission and approval of an ANX-514 NDA by the FDA based on a single, additional clinical study, the continued development of ANX-514 by ADVENTRX, including additional clinical and manufacturing work, and ADVENTRX's ability to fund such activities, ADVENTRX's belief that the short period of higher exposure to total docetaxel concentrations observed early in the treatment cycle with ANX-514 in Study 514-01 does not adversely affect the safety or efficacy of ANX-514 relative to Taxotere, the regulatory approval and commercial launch of Exelbine by ADVENTRX, and the potential for pipeline expansion through acquisition of new product candidates or technologies, including consummation of ADVENTRX's acquisition of SynthRx, Inc. Actual
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
2. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
3. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
4. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
5. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
6. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
7. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
8. ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11
9. ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
10. ADVENTRX Reports Third Quarter Financial Results
11. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
(Date:7/31/2014)... TB Alliance, a not-for-profit with the ... affordable treatments, announced the appointment of Willo ... Mr. Brock comes to TB Alliance having most ... for WWF International (formerly known as the World ... guide the TB Alliance,s resource development, advocacy and ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... June 14, 2011 Orthopedics This Week announced today ... News to supply Orthopedics This Week, the #1 source ... terminal subscribers including some of the most prominent investors ... The Bloomberg network includes portfolio managers, central bankers, finance ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ... the U.S. Food and Drug Administration (FDA) has extended ... for its review of the New Drug Application (NDA) ... The new PDUFA goal date is October 28, 2011. ...
Cached Medicine Technology:Orthopedics This Week Now on Bloomberg 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 3
(Date:7/31/2014)... 31, 2014 Dr. Andrew Lian-Jie Li ... of Dermatology, fellowship trained Mohs surgeon that has been ... , After extensive dermatology research training at the National ... Li completed his internship in internal medicine at the ... Pennsylvania in Philadelphia. Dr. Li pursued further training in ...
(Date:7/31/2014)... prevalence of heroin use has been rising steadily in ... Survey on Drug Use and Health, the number of ... 2007 (373,000) and 2012 (669,000). Emerging evidence suggests the ... who transition from oral and/or intranasal PO use to ... opioid use, and ultimately, heroin injection. This drug-use ...
(Date:7/31/2014)... Model moms are believers. PBS has a ... in the field have grown exponentially in the last two ... industry, there are associated myths that need to be busted. ... Frontier Nursing University . Celebrating 75 years in 2014, Frontier ... in the nation. “Frontier is changing the face of healthcare ...
(Date:7/31/2014)... UK (PRWEB) July 31, 2014 Infection ... the development and maintenance of products in the pharma, ... be performed by using various products and equipment types; ... spoilage of various materials and products. , The ... services is forecast to post a CAGR of about ...
(Date:7/31/2014)... By Amy Norton ... -- They may not have had fast food, TVs or ... arteries -- and a new research review speculates on some ... ancient Egypt, Peru, the Aleutian Islands and the American Southwest, ... of heart arteries from fatty substances that build up, eventually ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 2Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 3
... group of immature cells that persist in the adult ... mice that these cells undergo dramatic changes in ALS, ... reported November 17 online in Neuron shows that these ... life, eventually morphing into mature nervous system cells called ...
... HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- ... a striking effect on lowering blood pressure in heart ... drugs, Australian researchers report. Although this study only ... -- the authors believe the approach, which involves delivering ...
... Nov. 17 (HealthDay News) -- A new drug focused on the ... clinical trials, new research shows. If eventually approved by ... VX-770 would mark the first treatment that gets at what ... than just the symptoms. Only 4 to 5 percent of ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Resistance ... than aerobic exercise and offers other cardiovascular benefits, finds ... University in Boone, N.C., compared blood vessel (vascular) responses ... 10 repetitions of eight resistance exercises and 30 minutes ...
... 17 (HealthDay News) -- The U.S. Food and Drug Administration ... products are illegal. In warning letters to the companies, ... is an "unsafe food additive," and the companies risked further ... find support for the claim that the addition of caffeine ...
... to targeting diseases such as cancer has been announced by ... the potential for more targeted treatments following their identification of ... a human cell. The research teams from Germany and ... Publication on Nature Cell Biology ,s website. ...
Cached Medicine News:Health News:Mysterious cells may play role in ALS 2Health News:Nerve Zap to Kidneys Might Ease Stubborn Hypertension 2Health News:Nerve Zap to Kidneys Might Ease Stubborn Hypertension 3Health News:Drug Targets Faulty Process That Drives Cystic Fibrosis 2Health News:Drug Targets Faulty Process That Drives Cystic Fibrosis 3Health News:Resistance Exercise May Offer Different Cardio Benefits 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:Scientists announce new advance with potential for future cancer targeting 2
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
Medicine Products: